Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
Y Lu, X Yuan, M Wang, Z He, H Li, J Wang… - Journal of hematology & …, 2022 - Springer
The gut microbiota have long been recognized to play a key role in human health and
disease. Currently, several lines of evidence from preclinical to clinical research have …
disease. Currently, several lines of evidence from preclinical to clinical research have …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
Beyond immune checkpoint blockade: emerging immunological strategies
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
mosaic of single agents and combination immunotherapies. However, the lack of clinical …
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell …
Objective Programmed death 1 and its ligand 1 (PD-1/PD-L1) immunotherapy is promising
for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut …
for late-stage lung cancer treatment, however, the response rate needs to be improved. Gut …
The immunology of renal cell carcinoma
CM Díaz-Montero, BI Rini, JH Finke - Nature Reviews Nephrology, 2020 - nature.com
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …
Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors
Q Lei, D Wang, K Sun, L Wang… - Frontiers in cell and …, 2020 - frontiersin.org
In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …
Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets
NA di Meo, F Lasorsa, M Rutigliano, D Loizzo… - International Journal of …, 2022 - mdpi.com
Clear cell renal cell carcinoma (ccRCC) is the most frequent histological kidney cancer
subtype. Over the last decade, significant progress has been made in identifying the genetic …
subtype. Over the last decade, significant progress has been made in identifying the genetic …
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Oncogenesis is associated with intestinal dysbiosis, and stool shotgun metagenomic
sequencing in individuals with this condition might constitute a non-invasive approach for …
sequencing in individuals with this condition might constitute a non-invasive approach for …
[HTML][HTML] Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
Background Durable efficacy of immune checkpoint blockade (ICB) occurred in a small
number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of …
number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of …